Introduction: The Symptom Women Suffer in Silence
Of all the symptoms of menopause, vaginal and urogenital changes may be the most underreported and undertreated. Up to 80% of postmenopausal women experience genitourinary syndrome of menopause (GSM) — a term that encompasses vaginal dryness, burning, irritation, painful intercourse (dyspareunia), urinary urgency and frequency, and recurrent urinary tract infections.
Unlike hot flashes, which often improve over time, GSM is progressive. Without treatment, it gets worse with each passing year as the estrogen-dependent tissues of the vagina and urinary tract continue to thin, lose elasticity, and become increasingly fragile.
The good news: localized vaginal estradiol is one of the most effective, safest, and most well-tolerated treatments in all of HRT. Luvo offers two vaginal estradiol formulations — vaginal gel and vaginal tablets — specifically for this purpose.
What Is Genitourinary Syndrome of Menopause (GSM)?
GSM occurs because the vaginal and urethral tissues are highly estrogen-dependent. When estrogen levels drop during and after menopause, these tissues undergo significant changes.
The vaginal epithelium thins from multiple cell layers to just a few, becoming fragile and easily irritated. Vaginal pH rises from its normal acidic range (3.5–4.5) to neutral or alkaline levels, disrupting the protective microbial environment and increasing susceptibility to infections. Blood flow to the vaginal and urethral tissues decreases, reducing natural lubrication and tissue health. The vaginal walls lose elasticity and may actually narrow and shorten. The urethral lining thins, contributing to urinary symptoms.
These changes can profoundly affect quality of life and intimate relationships. Many women avoid sexual activity entirely because of pain, and urinary symptoms can restrict daily activities. Yet studies consistently show that fewer than 25% of affected women receive treatment — often because they don’t mention symptoms to their provider, or their provider doesn’t ask.
How Vaginal Estradiol Works
Vaginal estradiol delivers the hormone directly to the tissues that need it most. Unlike systemic estradiol (tablets, cream, or patches), vaginal formulations are designed for localized action with minimal absorption into the bloodstream.
When applied vaginally, estradiol is absorbed by the estrogen-receptor-rich cells of the vaginal epithelium. It stimulates cell proliferation and maturation, restoring the vaginal lining to a healthier, more resilient state. Vaginal pH normalizes, protective lactobacilli return, lubrication improves, and the tissue regains elasticity and blood flow.
The systemic absorption of vaginal estradiol is very low — significantly lower than oral or transdermal estradiol. Blood estradiol levels with vaginal formulations typically remain within the normal postmenopausal range. This is why vaginal estradiol is considered safe for many women who cannot use systemic HRT, including some breast cancer survivors (though this should always be discussed with an oncologist).
Luvo’s Two Vaginal Estradiol Options
Luvo offers two formulations for localized estradiol delivery.
Estradiol vaginal gel is applied intravaginally using a pre-measured applicator. The gel distributes evenly across the vaginal walls, providing broad tissue contact. Many women find the gel comfortable and easy to use. Application is typically daily for the initial treatment period, then reduced to a maintenance schedule of 2–3 times per week. The gel formulation can also provide some benefit to the external vulvar area during application.
Estradiol vaginal tablets are small tablets inserted into the vagina using a disposable applicator. They dissolve and release estradiol locally. The tablet format is clean, mess-free, and appeals to women who prefer a solid formulation over a gel. Like the gel, initial treatment is usually daily, transitioning to a maintenance schedule.
Both formulations are effective for treating vaginal dryness, painful intercourse, vaginal atrophy, and urinary symptoms. The choice between them often comes down to personal preference and comfort.
Explore Luvo’s estradiol vaginal gel and estradiol vaginal tablets.
Vaginal Estradiol vs. Systemic HRT: When You Need Which
Understanding whether you need localized therapy, systemic therapy, or both is an important conversation to have with your Luvo provider.
Vaginal estradiol alone is appropriate if your primary symptoms are urogenital — vaginal dryness, painful sex, urinary issues — and you don’t have significant hot flashes, sleep disruption, or other systemic symptoms. It’s also a good option for women who have contraindications to systemic estrogen or prefer to avoid it.
Systemic estradiol (tablets, cream, or patches) is needed if you have systemic symptoms like hot flashes, night sweats, mood changes, or bone density concerns. Systemic therapy also provides some benefit to vaginal tissues, though many women find that adding localized vaginal estradiol provides more complete urogenital relief.
Combination therapy — systemic plus vaginal — is appropriate for women who have both systemic and significant urogenital symptoms. The systemic dose is set for overall symptom management, while vaginal estradiol provides the concentrated local effect the vaginal tissues need.
Luvo’s program supports all three approaches, and your provider will recommend the strategy that best addresses your symptom profile. Visit the hormone replacement program page to get started.
.webp)
